INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56801, 'Lumateperone', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56877/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56802, 'Lurasidone', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56878/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56803, 'Macimorelin', 'Levodopa', 'Moderate', 'Drugs that directly affect the pituitary secretion of growth hormone (e.g., somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors such as aspirin and nonsteroidal anti-inflammatory drugs) and drugs that may transiently elevate growth hormone levels (e.g., clonidine, levodopa, insulin) may impact the accuracy of the macimorelin diagnostic test.', 'DDInter', 'Concomitant use of macimorelin with drugs affecting growth hormone levels should generally be avoided. A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration.', 'Others', 'Concomitant use of macimorelin with drugs affecting growth hormone levels should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56879/', '', 'Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More', 'Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56804, 'Magaldrate', 'Levodopa', 'Minor', 'Antacids and some oral aluminum, calcium, or magnesium containing preparations may increase the absorption of levodopa. The mechanisms may be related to increased gastric pH and/or decreased gastric emptying time, resulting in less gastric degradation of levodopa and more levodopa absorption from the small intestine. This effect may be beneficial in some patients, but also difficult to predict and monitor. For most patients, this interaction is not clinically significant and no specific intervention would be required. Dosing intervals could be spaced by at least 2 hours if it is preferred to avoid this interaction.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56880/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56805, 'Magnesium carbonate', 'Levodopa', 'Minor', 'Antacids and some oral aluminum, calcium, or magnesium containing preparations may increase the absorption of levodopa. The mechanisms may be related to increased gastric pH and/or decreased gastric emptying time, resulting in less gastric degradation of levodopa and more levodopa absorption from the small intestine. This effect may be beneficial in some patients, but also difficult to predict and monitor. For most patients, this interaction is not clinically significant and no specific intervention would be required. Dosing intervals could be spaced by at least 2 hours if it is preferred to avoid this interaction.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56881/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56806, 'Magnesium hydroxide', 'Levodopa', 'Minor', 'Antacids and some oral aluminum, calcium, or magnesium containing preparations may increase the absorption of levodopa. The mechanisms may be related to increased gastric pH and/or decreased gastric emptying time, resulting in less gastric degradation of levodopa and more levodopa absorption from the small intestine. This effect may be beneficial in some patients, but also difficult to predict and monitor. For most patients, this interaction is not clinically significant and no specific intervention would be required. Dosing intervals could be spaced by at least 2 hours if it is preferred to avoid this interaction.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56882/', '', 'Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56807, 'Magnesium oxide', 'Levodopa', 'Minor', 'Antacids and some oral aluminum, calcium, or magnesium containing preparations may increase the absorption of levodopa. The mechanisms may be related to increased gastric pH and/or decreased gastric emptying time, resulting in less gastric degradation of levodopa and more levodopa absorption from the small intestine. This effect may be beneficial in some patients, but also difficult to predict and monitor. For most patients, this interaction is not clinically significant and no specific intervention would be required. Dosing intervals could be spaced by at least 2 hours if it is preferred to avoid this interaction.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56883/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 'Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56808, 'Memantine', 'Levodopa', 'Minor', 'Memantine may theoretically enhance the pharmacologic effects of dopaminergic agents.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56884/', '', 'Rivastigmine, Galantamine, Donepezil, Tacrine, Ginkgo biloba, Aducanumab', 'Safinamide, Rasagiline, Selegiline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56809, 'Mepenzolate', 'Levodopa', 'Moderate', 'Anticholinergic agents may decrease the absorption and oral bioavailability of levodopa. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby increasing the gastric degradation of levodopa and reducing the amount available for absorption in the small intestine.', 'DDInter', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients. Pharmacologic response to levodopa should be monitored more closely whenever anticholinergic agents are added to or withdrawn from therapy, and the dosages of the drugs adjusted as necessary.', 'Absorption', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56885/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More', 'Papaverine, Alosetron, Isometheptene', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56810, 'Mesoridazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56886/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56811, 'Methazolamide', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56887/', '', 'Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, Ketoconazole, More', 'Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56812, 'Methdilazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56888/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56813, 'Methotrimeprazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56889/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56814, 'Methyldopa', 'Levodopa', 'Minor', 'Levodopa may enhance the antihypertensive effect of methyldopa. Data are conflicting regarding the benefit of adding methyldopa to the medical regimen of patients who have Parkinson''s disease and who are already receiving levodopa. Some patients improve, but others worsen. Clinicians should be aware that combination therapy increases the risk of hypotension and that its effectiveness is unpredictable in patients with Parkinson''s disease.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56890/', '', 'Ropinirole, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56815, 'Metoclopramide', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as metoclopramide may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, since they may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease.', 'Antagonism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56891/', '', 'Cisapride', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56816, 'Metolazone', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56892/', '', 'Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, Ketoconazole, More', 'Opicapone, Rotigotine, Tolcapone, Bromocriptine, Pergolide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56817, 'Metoprolol', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56893/', '', 'Acetylsalicylic acid, Ivabradine, Sotalol, Sotalol, Sotalol', 'Opicapone, Rotigotine, Tolcapone, Pergolide, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56818, 'Midazolam', 'Levodopa', 'Moderate', 'Benzodiazepines may decrease the therapeutic effects of levodopa in patients with Parkinson''s disease. The mechanism is unknown.', 'DDInter', 'Patients receiving this combination should be monitored for altered clinical response. The benzodiazepine should be discontinued if an interaction is suspected.', 'Others', 'Patients receiving this combination should be monitored for altered clinical response.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56894/', '', 'Nitrazepam, Zopiclone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56819, 'Minoxidil', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56895/', '', 'Tacrolimus, Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56820, 'Moexipril', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56896/', '', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pramipexole, Amantadine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56821, 'Molindone', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56897/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56822, 'Nadolol', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56898/', '', 'Sotalol, Sotalol', 'Opicapone, Rotigotine, Tolcapone, Entacapone, Pergolide, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56823, 'Naxitamab', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56899/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56824, 'Nebivolol', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56900/', '', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Pergolide, Pramipexole, Amantadine', 'Acetylsalicylic acid, Ivabradine, Sotalol, Sacubitril, Aliskiren, Sotalol, Sotalol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56825, 'Nelarabine', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56901/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 'Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56826, 'Nicardipine', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56902/', '', 'Nimodipine, Celecoxib', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56827, 'Nisoldipine', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56903/', '', 'Nimodipine, Celecoxib', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56828, 'Nitrofurantoin', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56904/', '', 'Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin', 'Apomorphine, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56829, 'Nitroprusside', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56905/', '', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56830, 'Norepinephrine', 'Levodopa', 'Moderate', 'Coadministration with levodopa may potentiate the cardiovascular effects of sympathomimetic agents (e.g., epinephrine, norepinephrine, isoproterenol, amphetamine). Additive increases in blood pressure and heart rate may occur due to enhanced sympathetic activity. However, data evaluating the interaction are not available.', 'DDInter', 'The use of levodopa with sympathomimetic agents should generally be avoided. If concomitant use is required, close monitoring of the cardiovascular system is recommended and the dose of the sympathomimetic agent may need to be reduced.', 'Synergism', 'The use of levodopa with sympathomimetic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56906/', '', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Dopamine, Methoxamine, Mephentermine', 'Apomorphine, Ropinirole, Cabergoline, Amantadine, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56831, 'Nortriptyline', 'Levodopa', 'Minor', 'Tricyclic antidepressants may slightly reduce the serum concentrations of levodopa and carbidopa and reduce their effects. The mechanism may be related to slowed gastric emptying and increased gastric degradation. Anecdotal reports also suggest that coadministration of tricyclic antidepressants and levodopa or carbidopa may occasionally result in hypertensive episodes; however, causality was not clearly established. The mechanism is unknown. Until more information is available, it may be prudent to monitor patients for altered efficacy and safety.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56907/', '', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56832, 'Olanzapine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56908/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56833, 'Olmesartan', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56909/', '', 'Sacubitril, Aliskiren', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56834, 'Opicapone', 'Levodopa', 'Moderate', 'When catechol-O-methyltransferase (COMT) inhibitors are administered together with levodopa/carbidopa, they may increase the relative bioavailability (AUC) of levodopa. This is due to a decrease in levodopa clearance resulting in a prolongation of the terminal elimination half-life of levodopa (from approximately 2 hours to 3.5 hours). Adverse effects such as dyskinesia, somnolence, and orthostatic hypotension may be potentiated. In the presence of the decarboxylase inhibitor carbidopa, COMT is the major metabolizing enzyme for levodopa.', 'DDInter', 'Although COMT inhibitors are intended for use with levodopa/carbidopa, clinicians should be aware that dose reduction of levodopa may be necessary during coadministration. This is especially true if the patient is experiencing dyskinesia induced by levodopa. Use with caution in patients with severe dyskinesia or dystonia. Likewise, when discontinuing a COMT inhibitor, monitor patients and consider adjustment of other dopaminergic therapies as needed. In addition, some authorities advise that opicapone should be administered as a once-daily dose at least one hour before or after combinations containing levodopa so as to avoid any interaction with the absorption of levodopa (AU, UK).', 'Metabolism', 'Although COMT inhibitors are intended for use with levodopa/carbidopa, clinicians should be aware that dose reduction of levodopa may be necessary during coadministration.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56910/', '', 'Amantadine, Opicapone, Cabergoline', 'Levodopa, Amantadine, Rotigotine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56835, 'Oxaliplatin', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56911/', '', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, More', 'Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56836, 'Oxazepam', 'Levodopa', 'Moderate', 'Benzodiazepines may decrease the therapeutic effects of levodopa in patients with Parkinson''s disease. The mechanism is unknown.', 'DDInter', 'Patients receiving this combination should be monitored for altered clinical response. The benzodiazepine should be discontinued if an interaction is suspected.', 'Others', 'Patients receiving this combination should be monitored for altered clinical response.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56912/', '', 'Amantadine, Cabergoline', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56837, 'Oxybutynin', 'Levodopa', 'Moderate', 'Anticholinergic agents may decrease the absorption and oral bioavailability of levodopa. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby increasing the gastric degradation of levodopa and reducing the amount available for absorption in the small intestine.', 'DDInter', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients. Pharmacologic response to levodopa should be monitored more closely whenever anticholinergic agents are added to or withdrawn from therapy, and the dosages of the drugs adjusted as necessary.', 'Absorption', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56913/', '', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More', 'Apomorphine, Opicapone, Rasagiline, Tolcapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56838, 'Ozanimod', 'Levodopa', 'Major', 'Levodopa is the precursor of dopamine, which in turn is converted to norepinephrine. As such, levodopa may precipitate severe hypertensive reactions in patients treated with nonselective monoamine oxidase inhibitors (MAOIs). The mechanism is enhanced peripheral catecholamine availability due to decreased degradation (MAOI activity) and increased synthesis (levodopa effect) of dopamine and probably also norepinephrine.', 'DDInter', 'The concomitant administration of carbidopa has been reported to prevent or blunt the hypertensive response by inhibiting peripheral conversion of levodopa to dopamine. However, some clinicians maintain that, with or without carbidopa, levodopa should not be used concurrently with nonselective MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with levodopa.', 'Synergism', 'The concomitant administration of carbidopa has been reported to prevent or blunt the hypertensive response by inhibiting peripheral conversion of levodopa to dopamine.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56914/', '', 'Ropinirole, Opicapone, Cabergoline, Tolcapone, Entacapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56839, 'Paclitaxel (protein-bound)', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56915/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56840, 'Paliperidone', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56916/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56841, 'Peginterferon alfa-2a', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56917/', '', 'Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Aldesleukin, Histamine, Pegfilgrastim, More', 'Apomorphine, Opicapone, Cabergoline, Amantadine, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56842, 'Peginterferon alfa-2b', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56918/', '', 'Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Aldesleukin, Histamine, Pegfilgrastim, More', 'Apomorphine, Opicapone, Cabergoline, Amantadine, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56843, 'Penbutolol', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56919/', '', 'Ropinirole, Opicapone, Cabergoline, Tolcapone, Entacapone, Rotigotine, Pergolide, Pramipexole, Amantadine', 'Sotalol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56844, 'Perindopril', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56920/', '', 'Ezetimibe, Niacin, Acetylsalicylic acid, Fenofibrate, Bempedoic acid', 'Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pramipexole, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56845, 'Perphenazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56921/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56846, 'Phenelzine', 'Levodopa', 'Major', 'Levodopa is the precursor of dopamine, which in turn is converted to norepinephrine. As such, levodopa may precipitate severe hypertensive reactions in patients treated with nonselective monoamine oxidase inhibitors (MAOIs). The mechanism is enhanced peripheral catecholamine availability due to decreased degradation (MAOI activity) and increased synthesis (levodopa effect) of dopamine and probably also norepinephrine.', 'DDInter', 'The concomitant administration of carbidopa has been reported to prevent or blunt the hypertensive response by inhibiting peripheral conversion of levodopa to dopamine. However, some clinicians maintain that, with or without carbidopa, levodopa should not be used concurrently with nonselective MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with levodopa.', 'Synergism', 'The concomitant administration of carbidopa has been reported to prevent or blunt the hypertensive response by inhibiting peripheral conversion of levodopa to dopamine.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56922/', '', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', 'Amantadine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56847, 'Phenylpropanolamine', 'Levodopa', 'Moderate', 'Coadministration with levodopa may potentiate the cardiovascular effects of sympathomimetic agents (e.g., epinephrine, norepinephrine, isoproterenol, amphetamine). Additive increases in blood pressure and heart rate may occur due to enhanced sympathetic activity. However, data evaluating the interaction are not available.', 'DDInter', 'The use of levodopa with sympathomimetic agents should generally be avoided. If concomitant use is required, close monitoring of the cardiovascular system is recommended and the dose of the sympathomimetic agent may need to be reduced.', 'Synergism', 'The use of levodopa with sympathomimetic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56923/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Entacapone, Tolcapone, Rotigotine, Pergolide, Pramipexole, Amantadine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56848, 'Phenytoin', 'Levodopa', 'Moderate', 'Phenytoin may decrease the therapeutic effects of levodopa. The mechanism of this interaction is not known.', 'DDInter', 'If phenytoin and levodopa must be used together, close observation for evidence of altered levodopa effects is recommended. Patients should be advised to notify their physician if they experience a worsening of their parkinsonian symptoms. Levodopa dosage increases or alternatives to phenytoin may be required if evidence of an interaction is observed.', 'Antagonism', 'If phenytoin and levodopa must be used together, close observation for evidence of altered levodopa effects is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56924/', '', 'Lacosamide', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56849, 'Pimozide', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56925/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56850, 'Pindolol', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56926/', '', 'Sotalol', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Pergolide, Pramipexole, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56851, 'Pitavastatin', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56927/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56852, 'Polatuzumab vedotin', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56928/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56853, 'Polythiazide', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56929/', '', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole', 'Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, Ketoconazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56854, 'Pomalidomide', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56930/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56855, 'Ponatinib', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56931/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56856, 'Pramipexole', 'Levodopa', 'Moderate', 'Pramipexole may potentiate the dopaminergic side effects of levodopa, resulting in development or exacerbation of dyskinesia. In clinical trials, other adverse effects such as hallucinations, orthostatic hypotension, extrapyramidal syndrome, insomnia, and dizziness were also increased in patients with advanced Parkinson''s disease treated with the combination compared to levodopa alone.', 'DDInter', 'A reduction of levodopa dosage should be considered during coadministration with pramipexole. In a controlled study in advanced Parkinson''s disease, the dosage of levodopa was reduced by an average of 27% from baseline.', 'Synergism', 'A reduction of levodopa dosage should be considered during coadministration with pramipexole.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56932/', '', 'Levodopa, Amantadine, Rotigotine, Cabergoline', 'Pramipexole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56857, 'Pravastatin', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56933/', '', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Apomorphine, Opicapone, Rasagiline, Tolcapone, Selegiline, Rotigotine, Bromocriptine, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56858, 'Prazosin', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56934/', '', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56859, 'Procarbazine', 'Levodopa', 'Major', 'Levodopa is the precursor of dopamine, which in turn is converted to norepinephrine. As such, levodopa may precipitate severe hypertensive reactions in patients treated with nonselective monoamine oxidase inhibitors (MAOIs). The mechanism is enhanced peripheral catecholamine availability due to decreased degradation (MAOI activity) and increased synthesis (levodopa effect) of dopamine and probably also norepinephrine.', 'DDInter', 'The concomitant administration of carbidopa has been reported to prevent or blunt the hypertensive response by inhibiting peripheral conversion of levodopa to dopamine. However, some clinicians maintain that, with or without carbidopa, levodopa should not be used concurrently with nonselective MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with levodopa.', 'Synergism', 'The concomitant administration of carbidopa has been reported to prevent or blunt the hypertensive response by inhibiting peripheral conversion of levodopa to dopamine.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56935/', '', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, More', 'Apomorphine, Ropinirole, Cabergoline, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56860, 'Prochlorperazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56936/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56861, 'Procyclidine', 'Levodopa', 'Moderate', 'Anticholinergic agents may decrease the absorption and oral bioavailability of levodopa. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby increasing the gastric degradation of levodopa and reducing the amount available for absorption in the small intestine.', 'DDInter', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients. Pharmacologic response to levodopa should be monitored more closely whenever anticholinergic agents are added to or withdrawn from therapy, and the dosages of the drugs adjusted as necessary.', 'Absorption', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56937/', '', 'Apomorphine, Ropinirole, Cabergoline, Tolcapone, Entacapone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56862, 'Promazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56938/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56863, 'Promethazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56939/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56864, 'Propantheline', 'Levodopa', 'Moderate', 'Anticholinergic agents may decrease the absorption and oral bioavailability of levodopa. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby increasing the gastric degradation of levodopa and reducing the amount available for absorption in the small intestine.', 'DDInter', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients. Pharmacologic response to levodopa should be monitored more closely whenever anticholinergic agents are added to or withdrawn from therapy, and the dosages of the drugs adjusted as necessary.', 'Absorption', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56940/', '', 'Papaverine, Alosetron, Isometheptene', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56865, 'Propiomazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56941/', '', 'Nitrazepam, Zopiclone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56866, 'Dextropropoxyphene', 'Levodopa', 'Major', 'Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.', 'DDInter', 'Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.', 'Metabolism, Synergism', 'Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56942/', '', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 'Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56867, 'Propranolol', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56943/', '', 'Acetylsalicylic acid, Ivabradine, Sotalol, Sotalol, Sotalol', 'Opicapone, Rotigotine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56868, 'Protriptyline', 'Levodopa', 'Minor', 'Tricyclic antidepressants may slightly reduce the serum concentrations of levodopa and carbidopa and reduce their effects. The mechanism may be related to slowed gastric emptying and increased gastric degradation. Anecdotal reports also suggest that coadministration of tricyclic antidepressants and levodopa or carbidopa may occasionally result in hypertensive episodes; however, causality was not clearly established. The mechanism is unknown. Until more information is available, it may be prudent to monitor patients for altered efficacy and safety.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56944/', '', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56869, 'Quazepam', 'Levodopa', 'Moderate', 'Benzodiazepines may decrease the therapeutic effects of levodopa in patients with Parkinson''s disease. The mechanism is unknown.', 'DDInter', 'Patients receiving this combination should be monitored for altered clinical response. The benzodiazepine should be discontinued if an interaction is suspected.', 'Others', 'Patients receiving this combination should be monitored for altered clinical response.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56945/', '', 'Cabergoline', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56870, 'Quetiapine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56946/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56871, 'Quinapril', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56947/', '', 'Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Amantadine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56872, 'Ramipril', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56948/', '', 'Ezetimibe, Niacin, Acetylsalicylic acid, Fenofibrate, Bempedoic acid', 'Rotigotine, Bromocriptine, Opicapone, Tolcapone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56873, 'Rasagiline', 'Levodopa', 'Moderate', 'Rasagiline may potentiate the dopaminergic side effects of levodopa and exacerbate preexisting dyskinesia. The mechanism is rasagiline inhibition of the breakdown of dopamine via monoamine oxidase.', 'DDInter', 'Patients receiving rasagiline as an adjunct to levodopa may have increased dyskinesia, postural hypotension, and hallucinations. A reduction of the levodopa dosage may be considered based upon individual response. Patients should be cautioned to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Postural hypotension occurs most frequently in the first two months of rasagiline treatment or after a dose increase at any time and tends to decrease over time.', 'Synergism', 'Patients receiving rasagiline as an adjunct to levodopa may have increased dyskinesia, postural hypotension, and hallucinations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56949/', '', 'Apomorphine, Cabergoline, Amantadine, Rasagiline, Safinamide', 'Levodopa, Amantadine, Rotigotine, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56874, 'Remimazolam', 'Levodopa', 'Moderate', 'Benzodiazepines may decrease the therapeutic effects of levodopa in patients with Parkinson''s disease. The mechanism is unknown.', 'DDInter', 'Patients receiving this combination should be monitored for altered clinical response. The benzodiazepine should be discontinued if an interaction is suspected.', 'Others', 'Patients receiving this combination should be monitored for altered clinical response.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56950/', '', 'Amantadine, Cabergoline', 'Nitrazepam, Zopiclone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56875, 'Reserpine', 'Levodopa', 'Minor', 'Limited data suggest that reserpine may block the antiparkinsonian effects of levodopa. The mechanism is believed to be reserpine-induced depletion of brain dopamine. In general, however, alternative antihypertensive therapy is recommended for patients in whom levodopa is required.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56951/', '', 'Ropinirole, Opicapone, Amantadine, Rasagiline, Tolcapone, Entacapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56876, 'Risperidone', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56952/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56877, 'Rosuvastatin', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56953/', '', 'Ezetimibe, Niacin, Acetylsalicylic acid, Fenofibrate, Bempedoic acid, Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, More', 'Apomorphine, Opicapone, Cabergoline, Rasagiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56878, 'Sapropterin', 'Levodopa', 'Moderate', 'Coadministration of sapropterin and levodopa has been associated with neurologic adverse effects. The mechanism of interaction has not been described.', 'DDInter', 'Caution is advised if sapropterin is prescribed to patients receiving levodopa.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56954/', '', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Zinc acetate, Phenylbutyric acid, More', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56879, 'Scopolamine', 'Levodopa', 'Moderate', 'Anticholinergic agents may decrease the absorption and oral bioavailability of levodopa. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby increasing the gastric degradation of levodopa and reducing the amount available for absorption in the small intestine.', 'DDInter', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients. Pharmacologic response to levodopa should be monitored more closely whenever anticholinergic agents are added to or withdrawn from therapy, and the dosages of the drugs adjusted as necessary.', 'Absorption', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56955/', '', 'Nitrazepam, Zopiclone, Tropicamide, Ketorolac, Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', 'Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56880, 'Secnidazole', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56956/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 'Trimetrexate, Quinacrine, Nitazoxanide, Atovaquone, Tetracycline, Fluconazole, Cefepime, Norfloxacin, Ciprofloxacin, Cefuroxime, Cefixime, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56881, 'Selegiline', 'Levodopa', 'Moderate', 'When used as an adjunct to levodopa/carbidopa in the treatment of Parkinson''s disease, selegiline may enhance levodopa-associated side effects in some patients. The presumed mechanism is enhanced peripheral catecholamine availability due to decreased degradation (MAOI activity) and increased synthesis (levodopa effect) of dopamine and, probably, norepinephrine.', 'DDInter', 'Two to three days after adding selegiline to the regimen, the levodopa/carbidopa dosage may require reduction by 10% to 30%. It has been suggested that the dosage reduction should be gradual in increments of 10% every 3 to 4 days and concurrent use should be avoided in patients with postural hypotension, frequent falls, confusion, and dementia. Due to the risks of nonselective MAO inhibition and drug interactions, selegiline doses should not exceed 10 mg/day. In addition, some authorities also recommend avoiding this combination in patients with severe cardiovascular disease, arterial hypertension, hyperthyroidism, phaeochromocytoma, narrow-angle glaucoma, prostatic adenoma with appearance of residual urine, tachycardia, arrhythmias, severe angina pectoris, psychoses, advanced dementia and thyrotoxicosis.', 'Others', 'Two to three days after adding selegiline to the regimen, the levodopa/carbidopa dosage may require reduction by 10% to 30%.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56957/', '', 'Levodopa, Amantadine, Rotigotine, Cabergoline', 'Apomorphine, Safinamide, Selegiline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56882, 'Simvastatin', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56958/', '', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More', 'Apomorphine, Opicapone, Rasagiline, Tolcapone, Rotigotine, Bromocriptine, Safinamide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56883, 'Sodium bicarbonate', 'Levodopa', 'Minor', 'Antacids and some oral aluminum, calcium, or magnesium containing preparations may increase the absorption of levodopa. The mechanisms may be related to increased gastric pH and/or decreased gastric emptying time, resulting in less gastric degradation of levodopa and more levodopa absorption from the small intestine. This effect may be beneficial in some patients, but also difficult to predict and monitor. For most patients, this interaction is not clinically significant and no specific intervention would be required. Dosing intervals could be spaced by at least 2 hours if it is preferred to avoid this interaction.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56959/', '', 'Apomorphine, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More', 'Sorbitol, Sulfamethizole, Sodium citrate, Magnesium citrate, Mannitol, Sodium chloride, Chlorhexidine, Neomycin, Calcium chloride, Potassium chloride, Magnesium sulfate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56884, 'Sodium oxybate', 'Levodopa', 'Major', 'The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.', 'DDInter', 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.', 'Synergism', 'Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56960/', '', 'Safinamide, Amantadine, Rasagiline, Selegiline', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Dalfampridine, Riluzole, Inotersen, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56885, 'Solifenacin', 'Levodopa', 'Moderate', 'Anticholinergic agents may decrease the absorption and oral bioavailability of levodopa. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby increasing the gastric degradation of levodopa and reducing the amount available for absorption in the small intestine.', 'DDInter', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients. Pharmacologic response to levodopa should be monitored more closely whenever anticholinergic agents are added to or withdrawn from therapy, and the dosages of the drugs adjusted as necessary.', 'Absorption', 'Although certain anticholinergic agents may be used as adjunctive therapy in Parkinson''s disease, clinicians should recognize their potential to reduce the oral bioavailability of levodopa in some patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56961/', '', 'Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Safinamide', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56886, 'Solriamfetol', 'Levodopa', 'Moderate', 'Coadministration of solriamfetol with other drugs that increase dopamine levels or that bind directly to dopamine receptors may increase the risk of dopaminergic-related adverse effects. The mechanism of the interaction has not been reported, but it may involve synergistic or additive central dopaminergic effects.', 'DDInter', 'Caution is advised if solriamfetol is administered concomitantly with other dopaminergic drugs. Dosage adjustments and close patient monitoring should be considered whenever solriamfetol is used with other dopaminergic drugs.', 'Synergism', 'Caution is advised if solriamfetol is administered concomitantly with other dopaminergic drugs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56962/', '', 'Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Modafinil', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56887, 'Spironolactone', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56963/', '', 'Finerenone', 'Opicapone, Rotigotine, Tolcapone, Bromocriptine, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56888, 'Stavudine', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56964/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56889, 'Tamsulosin', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56965/', '', 'Finasteride, Silodosin, Dutasteride, Tadalafil, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More', 'Opicapone, Rotigotine, Tolcapone, Bromocriptine, Pergolide, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56890, 'Telbivudine', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56966/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56891, 'Telmisartan', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56967/', '', 'Sacubitril, Aliskiren', 'Opicapone, Rotigotine, Tolcapone, Bromocriptine, Pergolide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56892, 'Temazepam', 'Levodopa', 'Moderate', 'Benzodiazepines may decrease the therapeutic effects of levodopa in patients with Parkinson''s disease. The mechanism is unknown.', 'DDInter', 'Patients receiving this combination should be monitored for altered clinical response. The benzodiazepine should be discontinued if an interaction is suspected.', 'Others', 'Patients receiving this combination should be monitored for altered clinical response.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56968/', '', 'Nitrazepam, Zopiclone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56893, 'Teniposide', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56969/', '', 'Topotecan, Irinotecan', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56894, 'Terazosin', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56970/', '', 'Finasteride, Silodosin, Dutasteride, Tadalafil', 'Opicapone, Cabergoline, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Amantadine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56895, 'Teriflunomide', 'Levodopa', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56971/', '', 'Apomorphine, Opicapone, Cabergoline, Entacapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56896, 'Tetrabenazine', 'Levodopa', 'Moderate', 'Tetrabenazine can cause or exacerbate Parkinsonian symptoms and attenuate the pharmacologic effects of levodopa. The mechanism is reversible binding of human vesicular monoamine transporter type 2 (VMAT2) by tetrabenazine, which leads to depletion of monoamine in the central nervous system including dopamine.', 'DDInter', 'Concomitant use of tetrabenazine and levodopa should be avoided if possible. Tetrabenazine is not indicated for the treatment of levodopa-induced dyskinetic or choreiform movements, which should instead be treated by reducing the dosage of levodopa.', 'Antagonism', 'Concomitant use of tetrabenazine and levodopa should be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56972/', '', 'Amantadine, Cabergoline', 'Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56897, 'Thalidomide', 'Levodopa', 'Moderate', 'Thalidomide can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Peripheral neuropathy is a common, potentially severe side effect of thalidomide that may be irreversible.', 'DDInter', 'Caution is advised if thalidomide is used in combination with other neurotoxic agents. All patients treated with thalidomide should be examined at monthly intervals for the first three months of therapy and periodically thereafter to detect early signs of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Electrophysiological testing may be performed at baseline and every six months during therapy to detect asymptomatic neuropathy. Consideration should be given to immediate discontinuation of thalidomide in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Caution is advised if thalidomide is used in combination with other neurotoxic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56973/', '', 'Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, More', 'Safinamide, Amantadine, Selegiline, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56898, 'Thiethylperazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56974/', '', 'Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56899, 'Thioridazine', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56975/', '', 'Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (56900, 'Thiothixene', 'Levodopa', 'Moderate', 'Agents with central antidopaminergic activity such as phenothiazines, neuroleptics, and certain antiemetics may antagonize the pharmacologic effects of dopaminergic drugs, and vice versa. In addition, the central nervous system depressant and hypotensive effects of these agents may be additively or synergistically increased when taken together.', 'DDInter', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided. If coadministration is necessary, patients should be alerted to the possibility of excessive drowsiness and monitored for potentially diminished therapeutic response to both treatments. Patients treated for Parkinson''s disease should generally avoid antidopaminergic agents, particularly phenothiazines and older neuroleptic agents, since these agents may cause extrapyramidal reactions and exacerbate the symptoms of Parkinson''s disease. Likewise, patients with a major psychotic disorder should ordinarily not be treated with dopaminergic drugs because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.', 'Synergism', 'Concomitant use of dopaminergic drugs with antidopaminergic agents should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/56976/', '', 'Pimavanserin', '', 1767369485);
